Aidoc and Imbio Partner to Develop an AI Solution to Detect PE

December 3, 2020—Aidoc, a provider of enterprise artificial intelligence (AI) solutions, and Imbio, a provider of medical image analysis for pulmonary and cardiothoracic diseases, announced a partnership intended to provide an end-to-end AI solution for pulmonary embolism (PE) that will improve the efficiency and quality of PE detection and treatment.

In October 2020, Aidoc announced FDA clearance for its triaging and notification algorithms for flagging and communicating incidental PE. This AI solution issues real-time notifications of patients with suspected PE, providing an always-on safety net for unexpected cases. Along with PE, Aidoc offers FDA-cleared tools for the triage and notification of intracranial hemorrhage, cervical spine fractures, large vessel occlusion, and intra-abdominal free gas.

Imbio’s quantitative imaging analysis is intended for use for the automatic calculation of right ventricular to left ventricular (RV/LV) ratio.

According to Aidoc, the partnership with Imbio is intended to provide thoracic radiologists and PE management programs timely notification of PE cases combined with automated RV/LV ratio calculations to potentially improve patient severity assessment and expedite treatment.

The combined Aidoc and Imbio product is an investigational device that is limited by Federal law to investigational use, advised the company.